CODX

Co-Diagnostics Inc

Add to Watchlist

Advanced Chart

0.430

+0.013(3.117%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.469

Open

0.4394

VWAP

0.44

Vol

5.01M

Mkt Cap

16.57M

Low

0.4045

Amount

2.20M

EV/EBITDA(TTM)

Total Shares

31.28M

698.68K

EV/OCF(TTM)

P/S(TTM)

13.15

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

300.00K

+496.66%

-0.120

-50%

150.00K

+0.45%

-0.125

-65.28%

150.00K

-76.6%

-0.155

-51.56%

Estimates Revision

The market is revising Upward the revenue expectations for Co-Diagnostics, Inc. (CODX) for FY2025, with the revenue forecasts being adjusted by 140.85% over the past three months. During the same period, the stock price has changed by 53.79%.

Revenue Estimates for FY2025

Revise Upward

+140.85%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+8.96%

In Past 3 Month

Stock Price

Go Up

+53.79%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast CODX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CODX is 0.50 USD with a low forecast of 0.50 USD and a high forecast of 0.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

Current: 0.430

Low

0.50

Averages

0.50

High

0.50

Current: 0.430

Low

0.50

Averages

0.50

High

0.50

HC Wainwright & Co.

Yi Chen

Hold

Maintains

$1.5 → $1

2025-03-28

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$1.5 → $1

2025-03-28

Maintains

Hold

Reason

HC Wainwright & Co.

Yi Chen

Hold

Reiterates

$1.5

2024-11-11

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$1.5

2024-11-11

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Co-Diagnostics Inc (CODX.O) is -0.83, compared to its 5-year average forward P/E of 6.52. For a more detailed relative valuation and DCF analysis to assess Co-Diagnostics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

6.52

Current PE

-0.83

Overvalued PE

24.15

Undervalued PE

-11.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

5.87

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

23.98

Undervalued EV/EBITDA

-12.24

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.58

Current PS

27.34

Overvalued PS

23.21

Undervalued PS

-0.04

Financials

Annual

Quarterly

FY2025Q2

YoY :

-93.87%

162.91K

Total Revenue

FY2025Q2

YoY :

+4.92%

-8.06M

Operating Profit

FY2025Q2

YoY :

+1.72%

-7.73M

Net Income after Tax

FY2025Q2

YoY :

-8.00%

-0.23

EPS - Diluted

FY2025Q2

YoY :

+63.85%

-8.69M

Free Cash Flow

FY2025Q2

YoY :

-224.36%

-98.59

Gross Profit Margin - %

FY2025Q2

YoY :

+1051.72%

-3.31K

FCF Margin - %

FY2025Q2

YoY :

+1558.92%

-4.75K

Net Margin - %

FY2025Q2

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

CODX News & Events

Events Timeline

2025-09-17 (ET)

2025-09-17

09:49:54

Co-Diagnostics sets price for 9.62 million shares at $0.40 in registered direct offering

2025-09-16 (ET)

2025-09-16

09:32:06

Co-Diagnostics Enters MoU with Partner in Saudi Arabia

2025-09-11 (ET)

2025-09-11

09:46:01

Co-Diagnostics Conducts In Silico Analysis of Primer Sets for Chikungunya Virus

News

8.5

09-18PRnewswire

PinnedCo-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

8.5

09-17Newsfilter

PinnedCo-Diagnostics, Inc. Reveals Pricing for $3.8 Million Registered Direct Offering of Common Stock at Market Rate According to Nasdaq Regulations

4.0

09-17Benzinga

D. Boral Capital Reiterates Buy Rating on Co-Diagnostics with $10 Price Target Intact

People Also Watch

Huadi International Group Co., Ltd.

UTStarcom Holdings Corp

Enlivex Therapeutics Ltd

Kentucky First Federal Bancorp

Neurosense Therapeutics Ltd

Trio-Tech International

5.480

USD

+6.82%

FAQ

What is Co-Diagnostics Inc (CODX) stock price today?

The current price of CODX is 0.43 USD — it has increased 3.12 % in the last trading day.

CODX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

CODX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Co-Diagnostics Inc (CODX) stock price today?

What is Co-Diagnostics Inc (CODX)'s business?

What is the price predicton of CODX Stock?

What is Co-Diagnostics Inc (CODX)'s revenue for the last quarter?

What is Co-Diagnostics Inc (CODX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Co-Diagnostics Inc (CODX)'s fundamentals?

How many employees does Co-Diagnostics Inc (CODX). have?

What is Co-Diagnostics Inc (CODX) market cap?